AveXis (NASDAQ:AVXS) Getting Somewhat Favorable News Coverage, Analysis Shows
News headlines about AveXis (NASDAQ:AVXS) have been trending somewhat positive on Saturday, Accern Sentiment Analysis reports. The research firm ranks the sentiment of news coverage by monitoring more than twenty million news and blog sources in real time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. AveXis earned a news impact score of 0.15 on Accern’s scale. Accern also gave media stories about the company an impact score of 46.7363682512146 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the stock’s share price in the next few days.
Here are some of the media stories that may have impacted Accern’s analysis:
- Jefferies Group LLC Reaffirms “Buy” Rating for AveXis, Inc. (NASDAQ:AVXS) (americanbankingnews.com)
- AveXis, Inc. (NASDAQ:AVXS) Price Target Raised to $130.00 (americanbankingnews.com)
- Edited Transcript of AVXS earnings conference call or presentation 10-Aug-17 8:30pm GMT (finance.yahoo.com)
- AveXis, Inc. (AVXS) Given Average Rating of “Buy” by Analysts (americanbankingnews.com)
- AveXis, Inc. (AVXS) Announces Earnings Results (americanbankingnews.com)
Several research analysts recently issued reports on AVXS shares. Jefferies Group LLC reaffirmed a “buy” rating and set a $92.00 target price on shares of AveXis in a research report on Wednesday, April 19th. Citigroup Inc. started coverage on AveXis in a research report on Tuesday, May 23rd. They set a “buy” rating and a $90.00 target price for the company. Zacks Investment Research raised AveXis from a “sell” rating to a “hold” rating in a research report on Thursday, July 13th. BMO Capital Markets reissued an “outperform” rating and issued a $95.00 price objective on shares of AveXis in a research report on Friday, June 16th. Finally, Sanford C. Bernstein assumed coverage on AveXis in a research report on Thursday, July 27th. They issued an “outperform” rating and a $108.00 price objective for the company. Two research analysts have rated the stock with a hold rating and ten have issued a buy rating to the company. AveXis has an average rating of “Buy” and a consensus target price of $100.70.
AveXis (NASDAQ AVXS) traded down 2.37% on Friday, hitting $89.49. The stock had a trading volume of 673,773 shares. The stock’s 50-day moving average is $85.66 and its 200-day moving average is $73.89. AveXis has a 52-week low of $32.31 and a 52-week high of $97.77. The company’s market cap is $2.48 billion.
AveXis (NASDAQ:AVXS) last released its quarterly earnings results on Thursday, August 10th. The company reported ($2.07) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.97) by $1.10. During the same period in the prior year, the company earned ($0.68) EPS. Analysts expect that AveXis will post ($4.36) earnings per share for the current year.
In other AveXis news, VP Sukumar Nagendran sold 1,780 shares of the firm’s stock in a transaction that occurred on Thursday, June 1st. The shares were sold at an average price of $70.91, for a total transaction of $126,219.80. Following the completion of the transaction, the vice president now owns 1,780 shares of the company’s stock, valued at $126,219.80. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. Insiders have sold 5,340 shares of company stock valued at $434,872 in the last ninety days. Insiders own 18.60% of the company’s stock.
WARNING: “AveXis (NASDAQ:AVXS) Getting Somewhat Favorable News Coverage, Analysis Shows” was reported by Watch List News and is owned by of Watch List News. If you are reading this piece of content on another site, it was copied illegally and republished in violation of US & international trademark & copyright law. The correct version of this piece of content can be viewed at https://www.watchlistnews.com/avexis-nasdaqavxs-getting-somewhat-favorable-news-coverage-analysis-shows/1478242.html.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.